Trevi Therapeutics, Inc. TRVI Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s financing cash flow?
- Trevi Therapeutics, Inc. (TRVI) reported financing cash flow of $222K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Trevi Therapeutics, Inc.'s financing cash flow decreased by 97.4% year-over-year, from $8.71M to $222K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Trevi Therapeutics, Inc.'s financing cash flow has grown at a 79.9% compound annual growth rate (CAGR), from $20.78M to $121.01M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.